Use of dulaglutide in a pregnant woman with type 2 diabetes until third trimester of pregnancy

In the last decades, the number of pregnant women affected by pregestational type 2 diabetes (T2D) has increased. This is due to the rising global prevalence of T2D, to the decreasing age of the onset of T2D and to the higher mean age of the first pregnancy. In the US, the prevalence of diabetes mellitus in women of childbearing age was reported to be between 3.1 and 6.8%, with pregestational diabetes recorded in 1–2% of all pregnancies.